How people choose in this industry
A formulator's sourcing team starts with a molecule and a grade. It looks for suppliers in a database, at pharma ingredient trade events, and by asking trade contacts. The short list then gets a request for a sample, a certificate of analysis, a drug master file reference where relevant, an impurity profile and a plant audit. A supplier whose first reply carries all of it has an edge over a larger name who needs three emails.
The technical team in R&D or quality assurance holds the real veto. They compare the impurity profile with the one they already use, check the particle size and polymorph if that matters, and decide whether a second source is worth the work. Purchase then negotiates price, but only for suppliers who passed the technical test.
For regulated-market buyers, the plant's inspection history and the right filings decide whether the conversation starts at all. For domestic buyers, supply reliability and a steady quality across batches count most.
The decision before implementation
Write decision rights into the engagement. Hiring, pay, pricing, and commercial authority are not transferred by implication.
Existing industry priorities to review
- Second-source qualification at formulators
- Contract manufacturers who buy APIs for others
- Overseas importers and distributors
- Repeat orders from trialled buyers
- Custom synthesis enquiries
These describe the industry's wider priorities. The written scope identifies which this service will address.